Ebola and Marburg Entry Inhibitor, a 4-(aminomethyl)benzamide-based compound, is a novel and potent entry inhibitor of Ebola and Marburg rirus infections. It has good metabolic stability in plasma and liver microsomes (rat and human), and did not inhibit CYP3A4 nor CYP2C9. It has the potential to be developed as therapeutic agents for the treatment and control of Ebola virus infections.
Physicochemical Properties
| Molecular Formula | C25H30F3N3O2 |
| Molecular Weight | 461.519816875458 |
| Exact Mass | 461.23 |
| Elemental Analysis | C, 65.06; H, 6.55; F, 12.35; N, 9.10; O, 6.93 |
| CAS # | 2479465-67-1 |
| PubChem CID | 154729054 |
| Appearance | White to off-white solid powder |
| LogP | 4.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 33 |
| Complexity | 625 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | VVJSZYWIEBDKTC-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C25H30F3N3O2/c1-18-8-10-31(11-9-18)23-7-6-21(16-22(23)25(26,27)28)29-24(32)20-4-2-19(3-5-20)17-30-12-14-33-15-13-30/h2-7,16,18H,8-15,17H2,1H3,(H,29,32) |
| Chemical Name | Benzamide,N-[4-(4-methyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-(4-morpholinylmethyl)- |
| Synonyms | VUN65671; VUN-65671; VUN 65671; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In A549 cells carrying luciferase reporter gene false type virus, EBOV/MARV-IN-1 (12.5 µM; 48 h) suppresses HIV/EBOV-GP (EC50=12 nM) and HIV/MARV-GP (EC50=180 nM), with modest cytotoxicity (SI =2088)[1]. |
| References |
[1]. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jul 9;63(13):7211-7225. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~216.68 mM ) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.42 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1668 mL | 10.8338 mL | 21.6675 mL | |
| 5 mM | 0.4334 mL | 2.1668 mL | 4.3335 mL | |
| 10 mM | 0.2167 mL | 1.0834 mL | 2.1668 mL |